Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

CRDF Cardiff Oncology Inc

3,45

0,05 (1,47%)

18 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Cardiff Oncology Charts.

Cardiff Oncology (NASDAQ:CRDF)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Cardiff Oncology Charts.

News Cardiff Oncology Inc

Form 8-K - Current report
Montag 6 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 18 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Dienstag 17 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 16 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 10 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering
Dienstag 10 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 10 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
Dienstag 10 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Dienstag 19 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
Donnerstag 7 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
Mittwoch 30 Oktober 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Cardiff Oncology Inc News-Artikel

Deutsche Telekom

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen